

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(API-01-20-US)

In Re Application of:)	
)	
Parrington, et al)	Examiner: Sean E. Aeder
)	
Serial No.: 10/510, 677)	
)	Group Art Unit: 1642
Filing Date: 09 APRIL 2003)	
)	
Title: MODIFIED CEA NUCLEIC ACID AND))	
EXPRESSION VECTORS)	

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Submitted via EFS-Web

To the Examiner:

Applicants respectfully submit this Information Disclosure Statement, PTO-1449 and copies of the reference cited therein. This Information Disclosure Statement is in compliance with the duty of candor as set forth in 37 C.F.R. § 1.56. It is requested that the documents be given careful consideration and that they be cited of record in the prosecution history of the present application so that they will appear on the face of the patent issuing of the present application.

In the judgment of the undersigned, portions of the references may be material to the examination of the pending claims. However, the references have not been reviewed in sufficient detail to make any other representation and, in particular, no representation is intended as to the relative importance of any portion of the references. This Statement is not a representation that the cited references have effective dates early enough to be "prior art" within the meaning of 35 U.S.C. §102 or §103.

CITED REFERENCES

U.S. Patents

4,923,808

6,407,063

Non-U.S. Patent Documents

WO 98/29556A1

WO 99/46992A1

WO 99/46988

Other Documents:

BERINSTEIN, et al. Carcinoembryonic Antigen as a Target for Therapeutic Anticancer Vaccines: A Review. *J. Clin. Oncol.* 20(8): 2197-2207 (2002)

DUBENSKY, et al. Delivery Systems for Gene-Based Vaccines. *Mol. Med.* 6(9): 723-732 (2000)

HODGE, et al. Diversified Prime and Boost Protocols Using Recombinant Vaccine Virus and Recombinant Non-Replicating Avian Pox Virus to Enhance T-Cell Immunity and Antitumor Responses. *Vaccine*, vol. 15, issue 6/7, pp. 759-768 (1997)

LEITNER, et al. Enhancement of Tumor-Specific Immune Response with Plasmid DNA Replicon Vectors. *Cancer Res.* 60: 51-55 (2000)

MARSHALL, J. Carcinoembryonic Antigen-Based Vaccines. *Semin. Oncol.* (suppl. 8): 30-36 (2003)

PARDOLL, D.M. Cancer vaccines. *Nat.Med.* 4: 525-531 (1998)

PARMIANI, et al. Cancer Immunotherapy with Peptide-Based Vaccines: What Have We Achieved? Where Are We Going? *J. Natl. Cancer Inst.* 94: 805-818 (2002)

VAN DER BURG, et al. Induction of p53-Specific Immune Responses in Colorectal Cancer Patients Receiving a Recombinant ALVAC-p53 Candidate Vaccine. *Clin. Cancer Res.* 8: 1019-1027 (2002)

Respectfully Submitted,

Date: March 2, 2010

By: /Patrick J. Halloran/
Patrick J. Halloran
Reg. No. 41,053

Patrick J. Halloran, Ph.D., J.D.
3141 Muirfield Road
Center Valley, PA 18034
Tel: 610-984-4751
Fax: 484-214-0164